AMENDMENT

In the Claims

The following list of claims replaces all prior versions.

1-58. (Canceled).

59. (Previously presented) A method for treating a human subject afflicted with supraventricular tachyarrhythmia, comprising administering to the human subject a therapeutically effective amount of JTV-519, thereby treating the human subject.

60. (Previously presented) The method of claim 59, wherein the amount of JTV-519 is from about 100 nM to about 1000 nM.

61. (Previously presented) The method of claim 59, wherein the administering is performed using a method selected from the group consisting of topical, intravenous, pericardial, oral, subcutaneous, and intraperitoneal administration.

62. (Previously presented) A method for inhibiting the onset of supraventricular tachyarrhythmia in a human subject, comprising administering to the human subject a prophylactically effective amount of JTV-519, thereby inhibiting the onset of supraventricular tachyarrhythmia in the human subject.

63. (Previously presented) The method of claim 62, wherein the amount of JTV-519 is from about 100 nM to about 1000 nM.

64. (Previously presented) The method of claim 62, wherein the administering is performed using a method selected from the group consisting of topical, intravenous, pericardial, oral, subcutaneous, and intraperitoneal administration.

65. (New) The method of claim 59, wherein the agent restores normal gating to a type 2 ryanodine receptor (RyR2) channel.

66. (New) The method of claim 59, wherein the agent inhibits dissociation of FKBP12.6 from a type 2 ryanodine (RyR2) receptor.

67. (New) The method of claim 59, wherein the agent enables FKBP12.6 to bind to PKA-phosphorylated type 2 ryanodine receptor (RyR2) channels.

68. (New) The method of claim 62, wherein the agent restores normal gating to a type 2 ryanodine receptor (RyR2) channel.

69. (New) The method of claim 62, wherein the agent inhibits dissociation of FKBP12.6 from a type 2 ryanodine (RyR2) receptor.

70. (New) The method of claim 62, wherein the agent enables FKBP12.6 to bind to PKA-phosphorylated type 2 ryanodine receptor (RyR2) channels.